Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 12/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.77 |
| ▸ | PRKACA | P17612 | 5/20 | 0.60 |
| ▸ | WNT3A | P56704 | 3/20 | 0.56 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.56 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437424 | 0.90 | ROCK1 (0.78) | ROCK1CYP3A4PRKACAWNT3A | |
| SCHEMBL439252 | 0.89 | ROCK1 (0.75) | ROCK1CYP3A4PRKACAROCK2ELOVL1 | |
| SCHEMBL436431 | 0.88 | ROCK1 (0.74) | ROCK1CYP3A4PRKACAWNT3AELOVL1 | |
| SCHEMBL439408 | 0.88 | ROCK1 (0.77) | ROCK1CYP3A4PRKACAWNT3AELOVL1 | |
| SCHEMBL439413 | 0.88 | ROCK1 (0.77) | ROCK1CYP3A4PRKACAWNT3AROCK2 | |
| SCHEMBL439202 | 0.87 | CYP3A4 (1.00) | ROCK1CYP3A4PRKACAWNT3AHTT | |
| SCHEMBL438825 | 0.87 | CYP3A4 (0.84) | ROCK1CYP3A4PRKACAWNT3AHTT | |
| SCHEMBL437420 | 0.87 | ROCK1 (0.78) | ROCK1CYP3A4PRKACAWNT3AROCK2 | |
| SCHEMBL439699 | 0.86 | CYP3A4 (0.78) | ROCK1CYP3A4PRKACAWNT3AROCK2 | |
| SCHEMBL439696 | 0.85 | CYP3A4 (0.72) | ROCK1CYP3A4PRKACAWNT3AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278306-B2 | C-met protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065213-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, MYLK | ROCK1 4/4885CYP3A4 3859/4885PRKACA 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.